{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T21:20:16Z","timestamp":1792876816351,"version":"4.5.0"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"am","delay-in-days":315,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008564","name":"Case Western Reserve University School of Medicine","doi-asserted-by":"publisher","award":["W81XWH1810618"],"award-info":[{"award-number":["W81XWH1810618"]}],"id":[{"id":"10.13039\/100008564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008564","name":"Case Western Reserve University School of Medicine","doi-asserted-by":"publisher","award":["W81XWH1910720"],"award-info":[{"award-number":["W81XWH1910720"]}],"id":[{"id":"10.13039\/100008564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006928","name":"The Ohio State University","doi-asserted-by":"publisher","award":["W81XWH2010065"],"award-info":[{"award-number":["W81XWH2010065"]}],"id":[{"id":"10.13039\/100006928","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.canlet.2024.216706","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T20:45:34Z","timestamp":1707252334000},"page":"216706","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"special_numbering":"C","title":["EZH2-mediated development of therapeutic resistance in cancer"],"prefix":"10.1016","volume":"586","author":[{"given":"Parminder","family":"Kaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eswar","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9492-3249","authenticated-orcid":false,"given":"Sanjay","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2024.216706_bib1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/path.1706","article-title":"Molecular mechanisms of drug resistance","volume":"205","author":"Longley","year":"2005","journal-title":"J. Pathol."},{"key":"10.1016\/j.canlet.2024.216706_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21093233","article-title":"Mechanisms of multidrug resistance in cancer chemotherapy","volume":"21","author":"Bukowski","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2024.216706_bib3","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1272\/jnms.JNMS.2020_87-508","article-title":"Drug resistance in cancer therapy and the role of epigenetics","volume":"87","author":"Asano","year":"2020","journal-title":"J. Nippon Med. Sch."},{"key":"10.1016\/j.canlet.2024.216706_bib4","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.gde.2016.03.013","article-title":"Emerging roles for Polycomb proteins in cancer","volume":"36","author":"Pasini","year":"2016","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.canlet.2024.216706_bib5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1101\/gad.173930.111","article-title":"PRC2 directly methylates GATA4 and represses its transcriptional activity","volume":"26","author":"He","year":"2012","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2024.216706_bib6","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ccr.2013.04.008","article-title":"Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells","volume":"23","author":"Kim","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2024.216706_bib7","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1227604","article-title":"EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent","volume":"338","author":"Xu","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.canlet.2024.216706_bib8","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1016\/j.celrep.2018.11.035","article-title":"Polycomb- and methylation-independent roles of EZH2 as a transcription activator","volume":"25","author":"Kim","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2024.216706_bib9","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1515\/hsz-2019-0436","article-title":"EZH2 function in immune cell development","volume":"401","author":"Nutt","year":"2020","journal-title":"Biol. Chem."},{"key":"10.1016\/j.canlet.2024.216706_bib10","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.1016\/j.celrep.2018.03.002","article-title":"Regulation of cellular senescence by polycomb chromatin modifiers through distinct DNA damage- and histone methylation-dependent pathways","volume":"22","author":"Ito","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2024.216706_bib11","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","article-title":"A novel target for cancer treatment","volume":"13","author":"Duan","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2024.216706_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216143","article-title":"A context-dependent crosstalk and transcriptional regulation in cancer","volume":"560","author":"Kaur","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.216706_bib13","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1158\/1541-7786.MCR-13-0546","article-title":"EZH2: not EZHY (easy) to deal","volume":"12","author":"Deb","year":"2014","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.canlet.2024.216706_bib14","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s11899-018-0466-6","article-title":"Emerging EZH2 inhibitors and their application in lymphoma","volume":"13","author":"Lue","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.canlet.2024.216706_bib15","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1111\/cas.14840","article-title":"The noncanonical role of EZH2 in cancer","volume":"112","author":"Huang","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2024.216706_bib16","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nature01075","article-title":"The polycomb group protein EZH2 is involved in progression of prostate cancer","volume":"419","author":"Varambally","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2024.216706_bib17","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2024.216706_bib18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11912-020-01003-9","article-title":"Clinical and biological features of neuroendocrine prostate cancer","volume":"23","author":"Yamada","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.canlet.2024.216706_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.115200","article-title":"Dual targeting of EZH2 and androgen receptor as a novel therapy for castration-resistant prostate cancer","volume":"404","author":"Shankar","year":"2020","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.canlet.2024.216706_bib20","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1182\/blood-2017-08-804344","article-title":"Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas","volume":"131","author":"Bisserier","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216706_bib21","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12935-021-01897-w","article-title":"Feedback activation of NF-KB signaling leads to adaptive resistance to EZH2 inhibitors in prostate cancer cells","volume":"21","author":"Jin","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.canlet.2024.216706_bib22","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/sj.ejhg.5200439","article-title":"The human EZH2 gene: genomic organisation and revised mapping in 7q35 within the critical region for malignant myeloid disorders","volume":"8","author":"Cardoso","year":"2000","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.canlet.2024.216706_bib23","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.molcel.2008.11.004","article-title":"Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms","volume":"32","author":"Margueron","year":"2008","journal-title":"Mol Cell"},{"key":"10.1016\/j.canlet.2024.216706_bib24","doi-asserted-by":"crossref","first-page":"85624","DOI":"10.18632\/oncotarget.12928","article-title":"Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2","volume":"7","author":"Christofides","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2024.216706_bib25","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1073\/pnas.1116418109","article-title":"Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)","volume":"109","author":"McCabe","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2024.216706_bib26","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/CAD.0000000000000166","article-title":"S-Adenosyl-L-methionine-competitive inhibitors of the histone methyltransferase EZH2 induce autophagy and enhance drug sensitivity in cancer cells","volume":"26","author":"Liu","year":"2015","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.canlet.2024.216706_bib27","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/nrd2974","article-title":"Protein methyltransferases as a target class for drug discovery","volume":"8","author":"Copeland","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2024.216706_bib28","doi-asserted-by":"crossref","first-page":"11606","DOI":"10.1073\/pnas.1933744100","article-title":"EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells","volume":"100","author":"Kleer","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2024.216706_bib29","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1159\/000087804","article-title":"Increased expression of EZH2, a polycomb group protein, in bladder carcinoma","volume":"75","author":"Arisan","year":"2005","journal-title":"Urol. Int."},{"key":"10.1016\/j.canlet.2024.216706_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115276","article-title":"EZH2 regulates cofilin activity and colon cancer cell migration by targeting ITGA2 gene","volume":"9","author":"Ferraro","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2024.216706_bib31","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1158\/2159-8290.CD-16-0164","article-title":"Oncogenic deregulation of EZH2 as an opportunity for targeted therapy in lung cancer","volume":"6","author":"Zhang","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2024.216706_bib32","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1182\/blood-2012-08-450494","article-title":"EZH2 overexpression in natural killer\/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity","volume":"121","author":"Yan","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216706_bib33","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.2005.01.5180","article-title":"EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast","volume":"24","author":"Bachmann","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.216706_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15020425","article-title":"EZH2: an accomplice of gastric cancer","volume":"15","author":"Yu","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2024.216706_bib35","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1476-4598-11-51","article-title":"MicroRNA-98 and microRNA-214 post-transcriptionally regulate enhancer of zeste homolog 2 and inhibit migration and invasion in human esophageal squamous cell carcinoma","volume":"11","author":"Huang","year":"2012","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2024.216706_bib36","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/PGP.0b013e31829c6574","article-title":"Increased EZH2 expression is associated with proliferation and progression of cervical cancer and indicates a poor prognosis","volume":"33","author":"Liu","year":"2014","journal-title":"Int. J. Gynecol. Pathol."},{"key":"10.1016\/j.canlet.2024.216706_bib37","doi-asserted-by":"crossref","first-page":"9211","DOI":"10.1158\/0008-5472.CAN-09-1622","article-title":"EZH2 is essential for glioblastoma cancer stem cell maintenance","volume":"69","author":"Suva","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.216706_bib38","doi-asserted-by":"crossref","first-page":"269","DOI":"10.7785\/tcrt.2012.500315","article-title":"EZH2 regulates the expression of p16 in the nasopharyngeal cancer cells","volume":"12","author":"Zhong","year":"2013","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.canlet.2024.216706_bib39","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/s41419-021-04118-4","article-title":"Histone acetyltransferase 1 promotes gemcitabine resistance by regulating the PVT1\/EZH2 complex in pancreatic cancer","volume":"12","author":"Sun","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2024.216706_bib40","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2024.216706_bib41","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/leu.2010.311","article-title":"EZH2 Y641 mutations in follicular lymphoma","volume":"25","author":"Bodor","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2024.216706_bib42","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1016\/j.febslet.2012.07.066","article-title":"A687V EZH2 is a gain-of-function mutation found in lymphoma patients","volume":"586","author":"Majer","year":"2012","journal-title":"FEBS Lett."},{"key":"10.1016\/j.canlet.2024.216706_bib43","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","article-title":"Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders","volume":"42","author":"Ernst","year":"2010","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2024.216706_bib44","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/ng.620","article-title":"Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes","volume":"42","author":"Nikoloski","year":"2010","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2024.216706_bib45","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.2651","article-title":"Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia","volume":"18","author":"Ntziachristos","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.canlet.2024.216706_bib46","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1182\/blood-2009-03-213496","article-title":"Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells","volume":"114","author":"Fiskus","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216706_bib47","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1182\/blood-2011-11-394932","article-title":"Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia","volume":"120","author":"Tanaka","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216706_bib48","article-title":"EZH2 mutations are related to low blast percentage in bone marrow and -7\/del(7q) in de novo acute myeloid leukemia","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2024.216706_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028585","article-title":"EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas","volume":"6","author":"Ryan","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2024.216706_bib50","doi-asserted-by":"crossref","first-page":"20980","DOI":"10.1073\/pnas.1012525107","article-title":"Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas","volume":"107","author":"Sneeringer","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2024.216706_bib51","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1021\/cb500548b","article-title":"Reaction coupling between wild-type and disease-associated mutant EZH2","volume":"9","author":"Swalm","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.canlet.2024.216706_bib52","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1186\/1471-2407-10-524","article-title":"Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma","volume":"10","author":"Wagener","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2024.216706_bib53","doi-asserted-by":"crossref","first-page":"5105","DOI":"10.1128\/MCB.00162-07","article-title":"Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells","volume":"27","author":"Shi","year":"2007","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2024.216706_bib54","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.molcel.2011.08.011","article-title":"Context-specific regulation of NF-kappaB target gene expression by EZH2 in breast cancers","volume":"43","author":"Lee","year":"2011","journal-title":"Mol Cell"},{"key":"10.1016\/j.canlet.2024.216706_bib55","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.molcel.2013.08.028","article-title":"PAF and EZH2 induce Wnt\/beta-catenin signaling hyperactivation","volume":"52","author":"Jung","year":"2013","journal-title":"Mol Cell"},{"key":"10.1016\/j.canlet.2024.216706_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1233953","article-title":"Non-canonical functions of EZH2 in cancer","volume":"13","author":"Zimmerman","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2024.216706_bib57","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ccell.2017.01.006","article-title":"Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 Axis","volume":"31","author":"Gardner","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2024.216706_bib58","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.oraloncology.2015.11.002","article-title":"EZH2 is associated with poor prognosis in head-and-neck squamous cell carcinoma via regulating the epithelial-to-mesenchymal transition and chemosensitivity","volume":"52","author":"Chang","year":"2016","journal-title":"Oral Oncol."},{"key":"10.1016\/j.canlet.2024.216706_bib59","first-page":"6662","article-title":"Inhibition of EZH2 reverses chemotherapeutic drug TMZ chemosensitivity in glioblastoma","volume":"7","author":"Fan","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.canlet.2024.216706_bib60","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ccr.2010.06.016","article-title":"Regulation of tumor angiogenesis by EZH2","volume":"18","author":"Lu","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2024.216706_bib61","first-page":"7","article-title":"Cancer statistics","volume":"70","author":"Siegel","year":"2020","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.canlet.2024.216706_bib62","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2024.216706_bib63","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2024.216706_bib64","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2024.216706_bib65","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2024.216706_bib66","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1158\/2159-8290.CD-NB2020-054","article-title":"Proof-of-Concept with PROTACs in prostate cancer","volume":"10","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2024.216706_bib67","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1038\/s41388-020-1270-z","article-title":"p300\/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer","volume":"39","author":"Liu","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2024.216706_bib68","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1038\/s41467-019-09784-9","article-title":"LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2\/STAT3 signaling","volume":"10","author":"Luo","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2024.216706_bib69","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/onc.2017.311","article-title":"EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer","volume":"37","author":"Yamaguchi","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2024.216706_bib70","doi-asserted-by":"crossref","first-page":"6651","DOI":"10.1158\/0008-5472.CAN-17-0899","article-title":"EZH2 modifies sunitinib resistance in renal cell carcinoma by kinome reprogramming","volume":"77","author":"Adelaiye-Ogala","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.216706_bib71","doi-asserted-by":"crossref","first-page":"652","DOI":"10.7150\/ijbs.19108","article-title":"Ezh2 acts as a tumor suppressor in kras-driven lung adenocarcinoma","volume":"13","author":"Wang","year":"2017","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.canlet.2024.216706_bib72","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13148-021-01052-2","article-title":"Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML\/MDS patients","volume":"13","author":"Stomper","year":"2021","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.canlet.2024.216706_bib73","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/nm.4247","article-title":"Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia","volume":"23","author":"Gollner","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.canlet.2024.216706_bib74","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.3390\/cells9071639","article-title":"EZH2 in myeloid malignancies","volume":"9","author":"Rinke","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2024.216706_bib75","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1084\/jem.20180570","article-title":"PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia","volume":"215","author":"Aries","year":"2018","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2024.216706_bib76","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1186\/s12885-020-07667-7","article-title":"EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells","volume":"20","author":"Gong","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2024.216706_bib77","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1101\/gad.1524107","article-title":"Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells","volume":"21","author":"Tan","year":"2007","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2024.216706_bib78","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1158\/1535-7163.MCT-09-0013","article-title":"DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation","volume":"8","author":"Miranda","year":"2009","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.canlet.2024.216706_bib79","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1158\/1535-7163.MCT-09-0479","article-title":"Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells","volume":"8","author":"Sun","year":"2009","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.canlet.2024.216706_bib80","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature11606","article-title":"EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations","volume":"492","author":"McCabe","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2024.216706_bib81","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ccr.2013.04.011","article-title":"EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation","volume":"23","author":"Beguelin","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2024.216706_bib82","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/nchembio.1084","article-title":"A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells","volume":"8","author":"Knutson","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.canlet.2024.216706_bib83","doi-asserted-by":"crossref","first-page":"21360","DOI":"10.1073\/pnas.1210371110","article-title":"Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation","volume":"109","author":"Qi","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2024.216706_bib84","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2024.216706_bib85","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1158\/1535-7163.MCT-13-0773","article-title":"Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma","volume":"13","author":"Knutson","year":"2014","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.canlet.2024.216706_bib86","doi-asserted-by":"crossref","first-page":"9928","DOI":"10.1021\/acs.jmedchem.6b01315","volume":"59","author":"Vaswani","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.canlet.2024.216706_bib87","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/blood-2014-06-581082","article-title":"Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia","volume":"125","author":"Xu","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216706_bib88","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1111\/cas.13326","article-title":"Novel orally bioavailable EZH1\/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor","volume":"108","author":"Honma","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2024.216706_bib89","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1021\/ml3003346","article-title":"Identification of potent, selective, cell-active inhibitors of the histone lysine methyltransferase EZH2","volume":"3","author":"Verma","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.canlet.2024.216706_bib90","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.molcel.2008.10.016","article-title":"EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency","volume":"32","author":"Shen","year":"2008","journal-title":"Mol Cell"},{"key":"10.1016\/j.canlet.2024.216706_bib91","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.chembiol.2013.09.013","article-title":"Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth","volume":"20","author":"Garapaty-Rao","year":"2013","journal-title":"Chem Biol"},{"key":"10.1016\/j.canlet.2024.216706_bib92","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1021\/cb400133j","article-title":"An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1","volume":"8","author":"Konze","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.canlet.2024.216706_bib93","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s40265-022-01800-5","article-title":"Valemetostat tosilate: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.canlet.2024.216706_bib94","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood.2022016862","article-title":"An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia\/lymphoma","volume":"141","author":"Izutsu","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216706_bib95","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1038\/nm.3968","article-title":"SWI\/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2","volume":"21","author":"Kim","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.canlet.2024.216706_bib96","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nm.3799","article-title":"Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers","volume":"21","author":"Bitler","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.canlet.2024.216706_bib97","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/s41556-022-00850-x","article-title":"EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis","volume":"24","author":"Wang","year":"2022","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.canlet.2024.216706_bib98","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/s41388-023-02618-5","article-title":"Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader","volume":"42","author":"Yu","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2024.216706_bib99","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1182\/blood.2022015668","article-title":"Noncanonical EZH2 drives retinoic acid resistance of variant acute promyelocytic leukemias","volume":"140","author":"Poplineau","year":"2022","journal-title":"Blood"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524000995?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524000995?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T16:13:11Z","timestamp":1759594391000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383524000995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":99,"alternative-id":["S0304383524000995"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2024.216706","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EZH2-mediated development of therapeutic resistance in cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2024.216706","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"216706"}}